HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.

scientific article published on 6 August 2014

HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/JPET.114.216556
P698PubMed publication ID25100752
P5875ResearchGate publication ID264633804

P2093author name stringSeiji Okazaki
Mie Kainoh
Koji Kawai
Mai Yagi
Mikiya Sato
Takehiro Takahashi
Yumiko Sekiya
Hiroki Kumagai
Aiko Nitta
Satoshi Sakami
Tomokatsu Iwamura
Junko Nakaki
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectobesityQ12174
hydroxysteroidQ2157080
glucose intoleranceQ2661464
P304page(s)181-189
P577publication date2014-08-06
P1433published inJournal of Pharmacology and Experimental TherapeuticsQ1500272
P1476titleHIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
P478volume351

Reverse relations

cites work (P2860)
Q33808884Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.
Q50068164Impact of Adrenal Steroids on Regulation of Adipose Tissue.
Q38397340New perspectives on the development of antiobesity drugs
Q36156958The expression of 11β-hydroxysteroid dehydrogenase type 1 is increased in experimental periodontitis in rats
Q36468624The increased ratio of 11β-hydroxysteroid dehydrogenase type 1 versus 11β-hydroxysteroid dehydrogenase type 2 in chronic periodontitis irrespective of obesity

Search more.